Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK completes major three-part transaction with Novartis
GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion
GlaxoSmithKline plc announces changes to its Board
GSK today announces that Sir Christopher Gent will step down as Chairman of GSK at the Company’s Annual General Meeting on 7 May 2015
Update on three-part transaction with Novartis
GSK today announces good progress on obtaining clearances and approvals to enable completion of its three-part transaction with Novartis
GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
GSK today announced that it has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland.
GSK and Theravance announce start of phase III lung function study with ‘closed’ triple combination treatment FF/UMEC/VI for COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a second global phase III study
GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™)
GSK today announced the submission to the European Medicines Agency of a variation to the Marketing Authorisation for eltrombopag (Revolade)
GSK announces positive overall survival results from phase III COMBI-d study of dabrafenib (Tafinlar™) and trametinib (Mekinist™) combination
GSK today announced overall survival results from COMBI-d which demonstrate a statistically significant reduction in the risk of death
Results announcement for the fourth quarter 2014
GSK delivers 2014 core EPS of 95.4p (-1% CER excluding divestments) and dividend of 80 pence per share (+3%)
Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
Organisations from South Africa, Zambia, Kenya and Uganda and Save the Children for innovations proven to help reduce deaths in under-fives
GSK statement on Oxford University phase I trial results of an Ebola candidate vaccine
Results from a phase I trial published by Oxford University show that a GSK/NIH Ebola vaccine demonstrated an acceptable safety profile
Regulatory update on three-part transaction with Novartis
GlaxoSmithKline plc (GSK) has today received clearance from the European Commission of its proposed three-part transaction with Novartis
Board Committee change
GSK announces that Sir Philip Hampton has been appointed Chairman of the Nominations Committee (the “Committee”) with effect from today
GSK extends its price-freeze commitment to ten years for countries graduating from Gavi support
New extended price freeze enables countries that graduate from Gavi support to continue to pay the same discounted price for GSK vaccines
Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial
Healthcare workers among those to be vaccinated in large-scale trial involving up to 30,000 people due to start in the coming weeks
GSK ‘confronts COPD’ to deliver new insights from across the globe to promote improved management of chronic lung disease
Data published today suggests, that long-term health outlook for patients with chronic obstructive pulmonary disease (COPD) has improved.
GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta™)
GSK announced the submission of sNDA to the US Food and Drug Administration for eltrombopag (Promacta™)
Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
GSK announced a phase III study to assess the efficacy of HZ/su, investigational vaccine for shingles, has met its primary endpoint.
New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine
Consortium includes GSK and research partners from Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne and the Bernhard-Nocht
GSK announces EU regulatory submission seeking extended indication for ambrisentan (Volibris®) in pulmonary arterial hypertension
GSK announced that it has filed a regulatory submission to the EMA for a variation to the Marketing Authorisation for ambrisentan(Volibris®)
GSK statement on Established Products Portfolio
GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.